Repurposing a cardiac test to help diagnose cardiac transthyretin amyloidosis
Featuring Dr. Frederick L. Ruberg, our senior cardiologist | Read more below https://www.cardiovascularbusiness.com/topics/imaging/resurrecting-tc-99m-pyp-cardiac-amyloidosis-therapies-emerge-old-test-gains-new
Proud to Present Dr. John Berk’s Research in hereditary ATTR Amyloidosis in New England Journal of Medicine
We are proud to announce 2 publications in the New England Journal of Medicine highlighting Dr. John Berk’s research in hereditary ATTR amyloidosis. You can find both articles linked below. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis NEJM | PubMed Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis NEJM | PubMed Congratulations to Dr. […]
3rd Annual Fit To Be Tied Race Wrap-Up
We would like to give a big shout-out to everyone that came out to the 3rd Annual Fit to Be Tied in support for Amyloidosis, which took place on May 20th, 2018 in Onondaga Lake Park in Liverpool, NY. We would also like to sincerely thank Ms. Floris Palmer and everyone who makes Fit to […]
Ann Peel Urges the US Congress to Support Amyloidosis Research for 2019
Ann Peel gave her testimony on amyloidosis to the House and Senate Appropriations Committees on April 26th, 2018. The testimony seeks support for Amyloidosis programs from Congress in the fiscal year 2019 Labor, Health Services and Education Appropriations bill. Please see her complete statement below. We are very grateful to Ann and Terry Peel for their dedication to […]
Dr. John Berk Speaks at 2018 AAN Meeting on Phase 3 Inotersen Results in hATTR
This past weekend, Dr. John Berk had the privilege of speaking at the 2018 American Academy of Neurology Annual Meeting in Los Angeles, California. Dr. Berk gave an impressive talk on the phase 3 inotersen results in hATTR to a packed house of neurologists. You can read more about the meeting here: https://www.aan.com/conferences-community/annual-meeting/
NEWS: Prothena Discontinues Development of NEOD001 for AL Amyloidosis
On April 23rd, 2018, Prothena Corporation plc announced the discontinuation of the development of NEOD001, an investigational monoclonal antibody targeting circulating soluble and deposited amyloid found in patients with AL Amyloidosis. The decision was made based on results from the Phase 2b PRONTO study and a fuity analysis of the Phase 3 VITAL study, according […]
Support The Amyloidosis Center on BU Giving Day 4/11/18
Today is BU Giving Day! Thanks to a group of generous donors, every gift from today (4/11) helps earn bonus funds for BU schools and colleges, teams, and programs (like us!) Consider contributing today: https://givingday.bu.edu/campaigns/amyloidosis-center-fund We are grateful for your continued support for The Amyloidosis Center.
The XVth International Symposium on March 26-29, 2018
I take this opportunity to reflect on the XVth International Symposium on Amyloidosis, Amyloid Research Winter to Blooming Spring, held from March 26-29, 2018 in Kumamoto, Japan. Eighteen members of our team, including students, post docs, grad students, basic and clinical research scientists, attended this symposium and presented their work. Reflecting on this meeting […]
11th Annual Bill Cunningham Race to Beat Amyloid – Saturday 3/3/18
Hi Everyone, Hope you’ll be able to join us for our race, raffle, and silent auction again this year. If you can forward this and/or share on Facebook, we’d be most appreciative. The registration page at BMC has been completely redeveloped and is much better to use. This year team registration is also available, and […]
Amyloidosis Patient Spotlight: Miles of Gratitude
“Miles of Gratitude” When the Kahn family’s patriarch, Michael, was diagnosed with Amyloid Light-chain (AL) amyloidosis, he was advised to arrange his final affairs. Amyloidosis is a group of rare diseases, any one of which occurs when misfolded proteins accumulate in the tissue of particular organs in the body. For Michael, it was his heart. […]